0001192482-19-000420.txt : 20191113
0001192482-19-000420.hdr.sgml : 20191113
20191113204829
ACCESSION NUMBER: 0001192482-19-000420
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20191108
FILED AS OF DATE: 20191113
DATE AS OF CHANGE: 20191113
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Oliva Adele C
CENTRAL INDEX KEY: 0001339379
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-39130
FILM NUMBER: 191215971
MAIL ADDRESS:
STREET 1: C/O QUAKER PARTNERS
STREET 2: 150 MONUMENT ROAD, SUITE 207
CITY: BALA CYNWYD
STATE: PA
ZIP: 19004
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: TELA Bio, Inc.
CENTRAL INDEX KEY: 0001561921
STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
IRS NUMBER: 455320061
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 1 GREAT VALLEY PARKWAY, SUITE 24
CITY: MALVERN
STATE: PA
ZIP: 19355
BUSINESS PHONE: 484-320-2930
MAIL ADDRESS:
STREET 1: 1 GREAT VALLEY PARKWAY, SUITE 24
CITY: MALVERN
STATE: PA
ZIP: 19355
4
1
edgar.xml
PRIMARY DOCUMENT
X0306
4
2019-11-08
0001561921
TELA Bio, Inc.
TELA
0001339379
Oliva Adele C
C/O QUAKER BIOVENTURES CAPITAL II, L.P.
150 MONUMENT ROAD, SUITE 207
BALA CYNWYD
PA
19004
1
0
1
0
Common Stock
2019-11-08
4
P
0
153846
13.00
A
888664
I
By Quaker Bioventures II, L.P.
Common Stock
2019-11-13
4
C
0
345489
A
1234153
I
By Quaker Bioventures II, L.P.
Common Stock
2019-11-13
4
C
0
516947
A
1751100
I
By Quaker Bioventures II, L.P.
Series A Preferred Stock
2019-11-13
4
C
0
8530145
0
D
Common Stock
345489
0
I
By Quaker Bioventures II, L.P.
Series B Preferred Stock
2019-11-13
4
C
0
12763434
0
D
Common Stock
516947
0
I
By Quaker Bioventures II, L.P.
Warrant (right to buy)
1.16
2019-11-13
4
C
0
446813
0
D
2017-01-18
2027-01-18
Series B Preferred Stock
446813
0
I
By Quaker Bioventures II, L.P.
Warrant (right to buy)
28.65
2019-11-13
4
C
0
446813
0
A
2019-11-13
2027-01-18
Common Stock
18096
446813
I
By Quaker Bioventures II, L.P.
Reflects 705,530 shares of common stock received as a payment-in-kind dividend on Series A Preferred Stock and Series B Preferred Stock exempt from reporting under Rule 16a-9(a).
The reporting person disclaims beneficial ownership of these securities except to the extent of her pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of all of the reported securities for the purposes of Section 16 or otherwise.
Shares of Series A Preferred Stock automatically converted into shares of Common Stock at a 1-for-1 conversion rate upon the closing of the Issuer's initial public offering and had no expiration date.
Shares of Series B Preferred Stock automatically converted into shares of Common Stock at a 1-for-1 conversion rate upon the closing of the Issuer's initial public offering and had no expiration date.
Reflects 1-for-24.69 reverse stock split which became effective on October 28, 2019.
Warrants exercisable for shares of Series B Preferred Stock automatically converted into warrants exercisable for shares of Common Stock upon the closing of the Issuer's initial public offering.
/s/ Nora Brennan as attorney-in-fact for Adele C. Oliva
2019-11-13